This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Inclusion Criteria:

• Chronic AD that has been present for ≥6 months
• Validated-Investigator's Global Assessment score of ≥3
• EASI of ≥16
• BSA of AD involvement of ≥10%

Exclusion Criteria:

• Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
• Use of certain medications
• Presence of skin comorbidities or other condition(s) that may interfere with study assessments
• Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry